

Andrew M Tonkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/139217/publications.pdf>

Version: 2024-02-01

118
papers

7,592
citations

109264

35
h-index

54882

84
g-index

146
all docs

146
docs citations

146
times ranked

10771
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
2	Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018, 379, 1509-1518.	13.9	770
3	Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018, 379, 1519-1528.	13.9	591
4	Effect of Aspirin on Disability-free Survival in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018, 379, 1499-1508.	13.9	392
5	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet, The</i> , 2018, 392, 1311-1320.	6.3	355
6	AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. <i>Medical Journal of Australia</i> , 2010, 192, 197-202.	0.8	250
7	Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2016, 134, 1637-1650.	1.6	205
8	Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. <i>European Heart Journal</i> , 2020, 41, 371-380.	1.0	180
9	Coronary Heart Disease in Patients With Low LDL-Cholesterol. <i>Circulation</i> , 2002, 105, 1424-1428.	1.6	169
10	Impact of Fine Particulate Matter (PM _{2.5}) Exposure During Wildfires on Cardiovascular Health Outcomes. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	168
11	Baseline Characteristics of Participants in the ASPREE (ASpirin in Reducing Events in the Elderly) Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 1586-1593.	1.7	143
12	A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 920-930.	0.8	136
13	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	0.8	133
14	Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. <i>Australian and New Zealand Journal of Public Health</i> , 2003, 27, 649-653.	0.8	123
15	Adverse effects of low-dose aspirin in a healthy elderly population. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 84-89.	2.3	120
16	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
17	Long-term risk stratification for survivors of acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2001, 38, 56-63.	1.2	112
18	Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2902-2908.	1.1	111

#	ARTICLE	IF	CITATIONS
19	D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease. <i>Circulation</i> , 2018, 138, 712-723.	1.6	93
20	Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 813-819.	1.7	63
21	Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long-Term Coronary Events Following Myocardial Infarction or Unstable Angina. <i>Journal of the American College of Cardiology</i> , 2014, 63, 345-354.	1.2	61
22	White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin. <i>Circulation</i> , 2005, 111, 1756-1762.	1.6	59
23	Susceptibility to Atrial Fibrillation:.. <i>Journal of Cardiovascular Electrophysiology</i> , 1998, 9, 423-435.	0.8	54
24	Persistent psychological distress and mortality in patients with stable coronary artery disease. <i>Heart</i> , 2017, 103, 1860-1866.	1.2	50
25	Changes in Lipoproteinâ€Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Longâ€term Intervention with Pravastatin in Ischemic Disease Study. <i>Journal of the American Heart Association</i> , 2013, 2, e000360.	1.6	47
26	Comparison of anthropometric measures as predictors of cancer incidence: A pooled collaborative analysis of 11 <sc>A</sc>ustralian cohorts. <i>International Journal of Cancer</i> , 2015, 137, 1699-1708.	2.3	46
27	A Systematic Review and Meta-analysis of the Factors Associated With Nonadherence and Discontinuation of Statins Among People Aged â‰¥65 Years. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 798-805.	1.7	46
28	Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. <i>Heart</i> , 2019, 105, 42-48.	1.2	45
29	Social isolation, social support and loneliness as predictors of cardiovascular disease incidence and mortality. <i>BMC Geriatrics</i> , 2021, 21, 711.	1.1	43
30	Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. <i>International Journal of Cardiology</i> , 2015, 201, 499-507.	0.8	42
31	Patterns of Association between Depressive Symptoms and Chronic Medical Morbidities in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1834-1841.	1.3	41
32	The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice. <i>Heart Failure Reviews</i> , 2016, 21, 675-697.	1.7	39
33	VALIDATION OF AN ECHOCARDIOGRAPHIC ASSESSMENT OF CARDIAC FUNCTION FOLLOWING MODERATE SIZE MYOCARDIAL INFARCTION IN THE RAT. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1996, 23, 570-572.	0.9	37
34	Effects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>Circulation</i> , 2010, 122, 850-852.	1.6	37
35	Can Medications be Safely Withdrawn in Patients With Stable Chronic Heart Failure? Systematic Review and Meta-analysis. <i>Journal of Cardiac Failure</i> , 2014, 20, 522-532.	0.7	36
36	The Î²-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 902-911.	2.1	36

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 975-982.	0.8	35
38	Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). <i>American Heart Journal</i> , 2016, 177, 58-65.	1.2	33
39	Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults. <i>Journal of the American College of Cardiology</i> , 2020, 76, 17-27.	1.2	27
40	The Effect of a Cardiovascular Polypill Strategy on Pill Burden. <i>Cardiovascular Therapeutics</i> , 2015, 33, 347-352.	1.1	25
41	The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross-sectional study. <i>Journal of Human Hypertension</i> , 2020, 34, 787-794.	1.0	25
42	Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>American Heart Journal</i> , 2012, 163, 508-514.	1.2	24
43	Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. <i>International Journal of Cardiology</i> , 2018, 270, 54-59.	0.8	24
44	Vascular Pathology and Osteoarthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2020, 47, 748-760.	1.0	24
45	The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective. <i>International Journal of Cardiology</i> , 2018, 267, 183-187.	0.8	23
46	Long-Term Blood Pressure Variability and Risk of Cognitive Decline and Dementia Among Older Adults. <i>Journal of the American Heart Association</i> , 2021, 10, e019613.	1.6	23
47	Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: Results from the LIPID study. <i>American Heart Journal</i> , 2006, 151, 1305-1312.	1.2	22
48	Does statin use have a disease modifying effect in symptomatic knee osteoarthritis? Study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 584.	0.7	21
49	Long-Term Blood Pressure Variability and Risk of Cardiovascular Disease Events Among Community-Dwelling Elderly. <i>Hypertension</i> , 2020, 76, 1945-1952.	1.3	21
50	Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals. <i>Genetics in Medicine</i> , 2020, 22, 1883-1886.	1.1	20
51	Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 858-868.	0.8	19
52	An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. <i>Medical Journal of Australia</i> , 2014, 201, 671-673.	0.8	18
53	Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. <i>Kidney International</i> , 2021, 99, 466-474.	2.6	18
54	Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model. <i>International Journal of Cardiology</i> , 2017, 248, 361-368.	0.8	17

#	ARTICLE	IF	CITATIONS
55	Health-related quality of life and incident cardiovascular disease events in community-dwelling older people: A prospective cohort study. <i>International Journal of Cardiology</i> , 2021, 339, 170-178.	0.8	17
56	Prediction of Cardiovascular and All-Cause Mortality at 10 Years in the Hypertensive Aged Population. <i>American Journal of Hypertension</i> , 2015, 28, 649-656.	1.0	16
57	Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: The LIPID study. <i>International Journal of Cardiology</i> , 2014, 172, 411-418.	0.8	15
58	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	1.0	15
59	Predictive Performance of a Polygenic Risk Score for Incident Ischemic Stroke in a Healthy Older Population. <i>Stroke</i> , 2021, 52, 2882-2891.	1.0	15
60	Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. <i>The Lancet Healthy Longevity</i> , 2022, 3, e109-e118.	2.0	15
61	Statins in the elderly. <i>Current Opinion in Cardiology</i> , 2014, 29, 372-380.	0.8	14
62	Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1393-1400.	0.8	14
63	Development of an Australian cardiovascular disease mortality risk score using multiple imputation and recalibration from national statistics. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 17.	0.7	14
64	Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study. <i>Journal of the American Heart Association</i> , 2022, 11, e020745.	1.6	14
65	The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. <i>International Journal of Cardiology</i> , 2019, 285, 1-5.	0.8	13
66	Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1289-1298.	2.3	13
67	Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in Individuals Aged 70 Years and Older. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, CIRCGEN121003429.	1.6	13
68	HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV. <i>BMC Infectious Diseases</i> , 2016, 16, 114.	1.3	12
69	Evaluating recruitment strategies for <sc>AUSPICE</sc> , a large Australian community-based randomised controlled trial. <i>Medical Journal of Australia</i> , 2019, 210, 409-415.	0.8	12
70	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	2.9	11
71	Genetic variants associated with inherited cardiovascular disorders among 13,131 asymptomatic older adults of European descent. <i>Npj Genomic Medicine</i> , 2021, 6, 51.	1.7	11
72	Cardiovascular risk prediction in healthy older people. <i>GeroScience</i> , 2022, 44, 403-413.	2.1	11

#	ARTICLE	IF	CITATIONS
73	Treatment of dyslipidemia. F1000prime Reports, 2014, 6, 17.	5.9	10
74	LDL Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) Risk. Clinical Pharmacology and Therapeutics, 2018, 104, 235-238.	2.3	10
75	Hypertension prevalence in patients attending tertiary pain management services, a registry-based Australian cohort study. PLoS ONE, 2020, 15, e0228173.	1.1	10
76	A multistate model of health transitions in older people: a secondary analysis of ASPREE clinical trial data. The Lancet Healthy Longevity, 2022, 3, e89-e97.	2.0	10
77	Reversing social disadvantage in secondary prevention of coronary heart disease. International Journal of Cardiology, 2014, 171, 346-350.	0.8	9
78	Role of Cardiac Biomarkers in Epidemiology and Risk Outcomes. Clinical Chemistry, 2021, 67, 96-106.	1.5	9
79	The metabolic syndrome(s)?: Current Atherosclerosis Reports, 2004, 6, 165-166.	2.0	8
80	Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study. CNS Drugs, 2019, 33, 685-694.	2.7	8
81	Familial Hypercholesterolemia in a Healthy Elderly Population. Circulation Genomic and Precision Medicine, 2020, 13, e002938.	1.6	8
82	Safety of Ceasing Aspirin Used Without a Clinical Indication After Age 70 Years: A Subgroup Analysis of the ASPREE Randomized Trial. Annals of Internal Medicine, 2022, 175, 761-764.	2.0	8
83	Digoxin Withdrawal Worsens Clinical Status in Stable Patients With Heart Failure Receiving Optimal Contemporaneous Therapy: A Randomized Controlled Trial. Journal of Cardiac Failure, 2015, 21, 779-781.	0.7	7
84	Attitudes of Patients and Prescribing Clinicians to Polypharmacy and Medication Withdrawal in Heart Failure. Journal of Cardiac Failure, 2016, 22, 743-744.	0.7	7
85	Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular disease. International Journal for Equity in Health, 2017, 16, 108.	1.5	7
86	Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. Kidney and Blood Pressure Research, 2017, 42, 1033-1044.	0.9	7
87	Effect of Atorvastatin on Knee Cartilage Volume in Patients With Symptomatic Knee Osteoarthritis: Results From a Randomized Placebo-Controlled Trial. Arthritis and Rheumatology, 2021, 73, 2035-2043.	2.9	7
88	Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. Atherosclerosis, 2022, 346, 68-74.	0.4	7
89	Trajectories of depressive symptoms in older adults and associated health outcomes. Nature Aging, 2022, 2, 295-302.	5.3	7
90	Into the future: diversifying lipid management. Lancet, The, 2012, 380, 1971-1974.	6.3	6

#	ARTICLE	IF	CITATIONS
91	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	1.4	6
92	Where on the Healthcare Continuum Should We Invest? The Case for Primary Care?. <i>Heart Lung and Circulation</i> , 2009, 18, 108-113.	0.2	5
93	Factors Associated With Treatment and Control of Hypertension in a Healthy Elderly Population Free of Cardiovascular Disease: A Cross-sectional Study. <i>American Journal of Hypertension</i> , 2020, 33, 350-361.	1.0	5
94	Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 467-476.	0.8	5
95	Polypharmacy in heart failure – Is reducing medication safe?. <i>International Journal of Cardiology</i> , 2016, 214, 529-530.	0.8	4
96	Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 57-64.	1.3	4
97	Mind the Gap: Mismatches Between Clinicians and Patients in Heart Failure Medication Management. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 37-46.	1.3	4
98	HIGH-SENSITIVITY CARDIAC TROPONIN T FOR THE DETECTION OF MYOCARDIAL INJURY AND RISK STRATIFICATION IN COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3145.	1.2	4
99	Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 337, 9-15.	0.8	4
100	Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2017, 6, e39.	0.5	4
101	Alcohol consumption and risks of cardiovascular disease and all-cause mortality in healthy older adults. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e230-e232.	0.8	4
102	B-type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	4
103	Impact of the 2017 American Heart Association and American College of Cardiology hypertension guideline in aged individuals. <i>Journal of Hypertension</i> , 2020, 38, 2527-2536.	0.3	3
104	Risk prediction: Increasingly important, but questions still remain. <i>Current Atherosclerosis Reports</i> , 2003, 5, 1-2.	2.0	1
105	Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?. <i>Medical Journal of Australia</i> , 2009, 191, 356-357.	0.8	1
106	A Pilot Study of Effects of Fruit Intake on Cardiovascular Risk Factors in Children. <i>ICAN: Infant, Child, & Adolescent Nutrition</i> , 2012, 4, 348-354.	0.2	1
107	PREDICTIVE PERFORMANCE OF A POLYGENIC RISK SCORE FOR INCIDENT ISCHEMIC STROKE IN A HEALTHY OLDER POPULATION. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1471.	1.2	1
108	Protective lipid-lowering variants in healthy older individuals without coronary heart disease. <i>Open Heart</i> , 2021, 8, e001710.	0.9	1

#	ARTICLE	IF	CITATIONS
109	Does Aspirin Prevent Incident Heart Failure in Healthy Older Adults? Examining the Evidence From the ASPREE Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	1
110	The need for medicine-based evidence as well as evidence-based medicine. <i>Current Atherosclerosis Reports</i> , 2001, 3, 97-98.	2.0	0
111	Unanswered Questions Arising from the Continuous Relationship Between Glucometabolic State and Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2006, 8, 439-440.	2.0	0
112	Temporal Changes in Characteristics, Treatment and Outcomes of Heart Failure Patients Undergoing Percutaneous Coronary Intervention Findings From Melbourne Interventional Group Registry. <i>Heart Lung and Circulation</i> , 2019, 28, 1018-1026.	0.2	0
113	Response by Simes et al to Letter Regarding Article, "D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease". <i>Circulation</i> , 2019, 139, 1245-1246.	1.6	0
114	Assessing and modifying cardiovascular risk in people who present to a chest pain clinic with non-cardiac causes. <i>Medical Journal of Australia</i> , 2021, 214, 263-264.	0.8	0
115	Title is missing!. , 2020, 15, e0228173.		0
116	Title is missing!. , 2020, 15, e0228173.		0
117	Title is missing!. , 2020, 15, e0228173.		0
118	Title is missing!. , 2020, 15, e0228173.		0